Buy Desipramine (Norpramin) Cas 50-47-5
Desipramine, sold under the brand name Norpramin among others, is a tricyclic antidepressant (TCA) used in the treatment of depression.[7] It acts as a relatively selective norepinephrine reuptake inhibitor, though it does also have other activities such as weak serotonin reuptake inhibitory, α1-blocking, antihistamine, and anticholinergic effects. The drug has not been considered a first-line treatment for depression since the introduction of selective serotonin reuptake inhibitor (SSRI) antidepressants, which have fewer side effects and are safer in overdose.
Medical uses
Desipramine is primarily used for the treatment of depression.[7] It may also be useful to treat symptoms of attention-deficit hyperactivity disorder (ADHD).[8] Evidence of benefit is only in the short term, and with concerns of side effects its overall usefulness is not clear.[9] Desipramine at very low doses is also used to help reduce the pain associated with functional dyspepsia.[10] It has also been tried, albeit with little evidence of effectiveness, in the treatment of cocaine dependence.[11] Evidence for usefulness in neuropathic pain is also poor.[12]
Side effects
Desipramine tends to be less sedating than other TCAs and tends to produce fewer anticholinergic effects such as dry mouth, constipation, urinary retention, blurred vision, and cognitive or memory impairments.[13]
Overdose
Desipramine is particularly toxic in cases of overdose, compared to other antidepressants.[14] Any overdose or suspected overdose of desipramine is considered to be a medical emergency and can result in death without prompt medical intervention.
Pharmacology
Pharmacodynamics
| Site | Ki (nM) | Species | Ref |
|---|---|---|---|
| SERTTooltip Serotonin transporter | 17.6–163 | Human | [16][17] |
| NETTooltip Norepinephrine transporter | 0.63–3.5 | Human | [16][17] |
| DATTooltip Dopamine transporter | 3,190 | Human | [16] |
| 5-HT1A | ≥6,400 | Human | [18][19] |
| 5-HT2A | 115–350 | Human | [18][19] |
| 5-HT2C | 244–748 | Rat | [20][21] |
| 5-HT3 | ≥2,500 | Rodent | [21][22] |
| 5-HT7 | >1,000 | Rat | [23] |
| α1 | 23–130 | Human | [18][24][17] |
| α2 | ≥1,379 | Human | [18][24][17] |
| β | ≥1,700 | Rat | [25][26] |
| Cav2.2 | 410 | Human | [27] |
| D1 | 5,460 | Human | [28] |
| D2 | 3,400 | Human | [18][24] |
| H1 | 60–110 | Human | [18][24][29] |
| H2 | 1,550 | Human | [29] |
| H3 | >100,000 | Human | [29] |
| H4 | 9,550 | Human | [29] |
| mAChTooltip Muscarinic acetylcholine receptor | 66–198 | Human | [18][24] |
| M1 | 110 | Human | [30] |
| M2 | 540 | Human | [30] |
| M3 | 210 | Human | [30] |
| M4 | 160 | Human | [30] |
| M5 | 143 | Human | [30] |
| σ1 | 1,990–4,000 | Rodent | [31][32] |
| σ2 | ≥1,611 | Rat | [15][32] |
| Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. | |||
Desipramine is a very potent and relatively selective norepinephrine reuptake inhibitor (NRI), which is thought to enhance noradrenergic neurotransmission.[33][34] Based on one study, it has the highest affinity for the norepinephrine transporter (NET) of any other TCA,[16] and is said to be the most noradrenergic[35] and the most selective for the NET of the TCAs.[33] The observed effectiveness of desipramine in the treatment of ADHD was the basis for the development of the selective NRI atomoxetine and its use in ADHD.[33]
Desipramine has the weakest antihistamine and anticholinergic effects of the TCAs.[36][35][37] It tends to be slightly activating/stimulating rather than sedating, unlike most others TCAs.[35] Whereas other TCAs are useful for treating insomnia, desipramine can cause insomnia as a side effect due to its activating properties.[35] The drug is also not associated with weight gain, in contrast to many other TCAs.[35] Secondary amine TCAs like desipramine and nortriptyline have a lower risk of orthostatic hypotension than other TCAs,[38][39] although desipramine can still cause moderate orthostatic hypotension.[40]
Pharmacokinetics
Desipramine is the major metabolite of imipramine and lofepramine.
AS 50-47-5 Desipramine | Products & Prices & Suppliers
-
- Desipramine, with the chemical formula C18H22N2, has the CAS number 50-47-5. It is a tricyclic antidepressant belonging to the class of dibenzazepines. Desipramine appears as a white crystalline powder with a slight amine odor. Its basic structure consists of three benzene rings fused together with a central nitrogen atom. This compound is slightly soluble in water. Desipramine may cause irritation to the skin and eyes. It is important to handle this chemical with care to avoid any potential harm. Safety precautions should be taken when working with desipramine to prevent exposure to high temperatures or flames. The primary hazard is the potential for adverse effects on human health. Proper measures should be taken to ensure its safe handling and disposal to protect both individuals and the environment.
Applicable Fields
Depression Treatment: Desipramine is primarily used as an antidepressant medication. Its purpose in this field involves its ability to regulate the levels of certain neurotransmitters in the brain, such as norepinephrine. The mechanism of action in depression treatment involves blocking the reuptake of these neurotransmitters, thereby increasing their availability and improving mood.
Pain Management: Desipramine has also been used in the management of chronic pain conditions. Its mechanism of action in pain management is not fully understood, but it is believed to involve the modulation of certain pain pathways in the central nervous system. Desipramine may help reduce the perception of pain and improve overall pain control.
Storage
Conditions: Store in a cool and dry place.
- Desipramine, with the chemical formula C18H22N2, has the CAS number 50-47-5. It is a tricyclic antidepressant belonging to the class of dibenzazepines. Desipramine appears as a white crystalline powder with a slight amine odor. Its basic structure consists of three benzene rings fused together with a central nitrogen atom. This compound is slightly soluble in water. Desipramine may cause irritation to the skin and eyes. It is important to handle this chemical with care to avoid any potential harm. Safety precautions should be taken when working with desipramine to prevent exposure to high temperatures or flames. The primary hazard is the potential for adverse effects on human health. Proper measures should be taken to ensure its safe handling and disposal to protect both individuals and the environment.
50-47-5 desipramine |
|
| Chemical Name | desipramine |
| Synonyms | 3-(10,11-dihydrodibenz(b,f)azepin-5-yl)methylpropylamine |
| Molecular Formula | C18H22N2 |
| Molecular Weight | 266.38 |
| InChl | InChI=1/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3 |
| CAS Registry Number | 50-47-5 |
| EINECS | 200-040-0 |
| Molecular Structure | ![]() |
| MSDS | Material Safety Data Sheet |
Desipramine

Content Navigation
Noradrenergic studies plagued by off-target sedation and dual-agent PK? Desipramine (CAS 50-47-5) is the definitive pre-metabolized secondary amine TCA with ≥20-fold NET selectivity vs SERT and 12-fold higher affinity than imipramine. Benefits: • Minimal H1/muscarinic binding avoids behavioral confounds. • Single stable agent for clean PET imaging and PK modeling. • CAD probe (pKa 10.65) for lysosomal trapping. Guaranteed analytical purity for reproducible assays.
CAS Number
Product Name
IUPAC Name
Molecular Formula
Molecular Weight
InChI
InChI Key
solubility
In water, 58.6 mg/l @ 24 °C.
3.96e-02 g/L
Synonyms
Canonical SMILES
Purity
Package Size
Desipramine (CAS 50-47-5) is a prototypical secondary amine tricyclic antidepressant (TCA) and a highly potent, selective norepinephrine transporter (NET) inhibitor. In commercial procurement and assay design, it serves as a critical benchmark compound for noradrenergic signaling, offering a distinct pharmacological and physicochemical profile compared to tertiary amine TCAs. Its utility spans from in vitro transporter binding assays to in vivo models of neuropathic pain and depression, where a stable, highly NET-selective probe is required to isolate specific neurochemical pathways without the broad-spectrum receptor promiscuity typical of earlier-generation compounds [1].
Substituting desipramine with its tertiary amine parent, imipramine, or other common TCAs like amitriptyline introduces severe confounding variables in both in vitro and in vivo settings. Imipramine undergoes rapid N-demethylation to form desipramine, creating a dual-agent system that complicates pharmacokinetic modeling and receptor-occupancy data [1]. Furthermore, tertiary TCAs possess significantly higher affinities for off-target histamine (H1) and muscarinic receptors, leading to unwanted sedative and anticholinergic effects that can mask or distort the primary noradrenergic endpoints in behavioral or physiological assays [2]. Consequently, procuring the pre-metabolized secondary amine is essential for reproducible, single-target noradrenergic research.
NET Binding Affinity & Selectivity
Desipramine demonstrates exceptional affinity for the norepinephrine transporter (NET), significantly outperforming its parent compound, imipramine. In radioligand binding assays, desipramine exhibits a NET Ki of approximately 2.9 nM, whereas imipramine shows a much weaker Ki of 35.2 nM [1]. Furthermore, desipramine maintains a high selectivity ratio over the serotonin transporter (SERT, Ki ~ 163 nM), unlike tertiary TCAs which display mixed inhibition profiles [2].
| Evidence Dimension | NET Binding Affinity (Ki) |
| Target Compound Data | Desipramine: ~2.9 nM |
| Comparator Or Baseline | Imipramine: ~35.2 nM |
| Quantified Difference | 12-fold higher affinity for NET |
| Conditions | [3H]norepinephrine transport inhibition in transfected HEK-293 cells |
Procuring desipramine ensures high-potency, selective NET blockade without the mixed SERT/NET profile of imipramine, crucial for isolating noradrenergic mechanisms.
Metabolic Stability Advantage
In vivo applications of imipramine are confounded by its rapid CYP450-mediated metabolism (via CYP1A2 and 2C19) into desipramine, creating a moving baseline of two active agents. Desipramine, as a secondary amine, bypasses this N-demethylation step and acts only as a weak CYP2D6 inhibitor, preventing the generation of a more potent secondary active metabolite [1].
| Evidence Dimension | Metabolic Stability and CYP Inhibition |
| Target Compound Data | Desipramine: Weak CYP2D6 inhibitor, no active N-demethylated metabolite |
| Comparator Or Baseline | Imipramine: Potent CYP1A2/2C19 inhibitor, rapidly converts to active desipramine |
| Quantified Difference | Elimination of dual-agent pharmacokinetic confounding |
| Conditions | In vivo systemic administration and hepatic metabolism models |
Using desipramine directly provides a stable, single-molecule pharmacological profile, essential for reproducible in vivo dosing and transporter-occupancy studies.
Low H1 and Muscarinic Receptor Binding
Tertiary amine TCAs are notorious for their high affinity to off-target receptors, which complicates behavioral data. Desipramine demonstrates significantly lower affinity for H1 histamine receptors (Ki ~ 26 nM) compared to amitriptyline (Ki ~ 4 nM) and doxepin (Ki ~ 0.7 nM) [1]. Additionally, desipramine has lower muscarinic receptor affinity (Ki ~ 100) than imipramine (Ki ~ 60) [2].
| Evidence Dimension | H1 Histamine Receptor Affinity (Ki) |
| Target Compound Data | Desipramine: ~26 nM |
| Comparator Or Baseline | Amitriptyline: ~4 nM; Doxepin: ~0.7 nM |
| Quantified Difference | 6.5-fold to 37-fold lower H1 affinity |
| Conditions | [3H]mepyramine displacement in mammalian brain membranes |
Buyers designing in vivo behavioral or pain models should select desipramine to isolate noradrenergic effects while minimizing confounding sedation and anticholinergic toxicity.
Lysosomal Trapping & FIASMA Activity
The structural difference between secondary and tertiary amines fundamentally alters their physicochemical properties, dictating cellular distribution. Desipramine possesses a higher pKa (~10.65) compared to imipramine (~9.40) [1]. This higher basicity alters its protonation state and lipophilic partition within acidic organelles, directly impacting its efficiency and accumulation dynamics as a functional inhibitor of acid sphingomyelinase (FIASMA) [2].
| Evidence Dimension | Acid Dissociation Constant (pKa) |
| Target Compound Data | Desipramine: pKa ~ 10.65 |
| Comparator Or Baseline | Imipramine: pKa ~ 9.40 |
| Quantified Difference | 1.25 log unit difference in basicity |
| Conditions | In silico and in vitro physicochemical profiling for membrane permeability |
For cellular assays targeting lysosomal lipid metabolism, the specific pKa of desipramine dictates its membrane accumulation and enzyme displacement rates differently than tertiary amines.
Selective NET Assays
Due to its 12-fold higher affinity for NET over imipramine and its >20-fold selectivity over SERT, desipramine serves as a benchmark standard for in vitro competitive binding assays and functional reuptake models where precise blockade of the norepinephrine transporter is required without serotonergic interference [1].
Neuropathic Pain and Behavioral Models
Desipramine provides a highly controlled TCA baseline for animal models of chronic pain and depression where researchers must isolate noradrenergic mechanisms. Its significantly lower affinity for H1 and muscarinic receptors prevents the profound sedative and anticholinergic effects seen with amitriptyline, ensuring that behavioral readouts are not confounded by off-target toxicity [2].
Pharmacokinetic and Receptor-Occupancy Benchmarking
Because desipramine is a stable secondary amine that does not metabolize into another highly active compound, it is highly suited for in vivo pharmacokinetic tracking and PET imaging validation, avoiding the dual-agent complexity inherent to imipramine administration [3].
Lysosomal FIASMA Research
Utilized as a cationic amphiphilic drug (CAD) standard in cell culture assays, desipramine’s specific pKa (10.65) allows it to be efficiently trapped in acidic lysosomes, making it a reliable tool compound for inducing and studying the functional inhibition of acid sphingomyelinase and subsequent phospholipidosis [4].
References
- [1] Galli, A., et al. ‘Kinetics and inhibitor insensitivity of [3H]norepinephrine (NE) transport…’ ResearchGate, 1995.
- [2] Tran, V. T., et al. ‘Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine.’ PNAS, 1978.
- [3] Gillman, P. K. ‘Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.’ British Journal of Pharmacology, 2007.
- [4] Fujikawa, M., et al. ‘A Strategy for in Silico Prediction of the Membrane Permeability of Drugs.’ Kobe University, 2014.
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Desipramine is a Tricyclic Antidepressant.
Desipramine is an oral tricyclic antidepressant that widely used in the therapy of depression. Desipramine can cause mild and transient serum enzyme elevations and is rare cause of clinically apparent acute cholestatic liver injury.
Desipramine is an active metabolite of imipramine, a tertiary amine and a synthetic tricyclic derivative of the antidepressant. Desipramine enhances monoamine neurotransmission in certain areas of the brain by inhibiting the re-uptake of noradrenaline and serotonin at the noradrenergic and serotoninergic nerve endings, respectively. It also induces sedation through histamine 1 receptor blockage and hypotension through beta-adrenergic blockage.
DESIPRAMINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA.
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
See also: Imipramine (related); Clomipramine (related); Trimipramine (related) … View More …
Desipramine is a tricyclic antidepressant primarily used to treat depression and certain anxiety disorders. It is a secondary amine derivative of imipramine, exhibiting a similar pharmacological profile but with distinct chemical properties and mechanisms of action. Desipramine is classified as a selective norepinephrine reuptake inhibitor, which enhances the availability of norepinephrine in the synaptic cleft, thereby alleviating depressive symptoms.
Desipramine was first synthesized in the 1950s as part of research into tricyclic antidepressants. It is derived from the dibenzazepine structure, which forms the backbone of many antidepressants in this class.
- Chemical Class: Tricyclic antidepressant
- Chemical Formula: C18H22N
- Molecular Weight: 262.38 g/mol
Methods
Desipramine can be synthesized through several methods, primarily involving the alkylation of 10,11-dihydro-5H-dibenz[b,f]azepine. One common approach is the reaction with 1-bromo-3-chloropropane in the presence of sodium amide, which facilitates the formation of desipramine via nucleophilic substitution.
Another method includes the synthesis of deuterium-labeled desipramine for pharmacokinetic studies, which involves deuteration at specific positions to trace metabolic pathways in biological systems .
Technical Details
The synthesis typically requires controlled conditions to ensure high yield and purity. For instance, reactions are often conducted under inert atmospheres to minimize oxidation and degradation of sensitive intermediates.
Data
- Melting Point: Approximately 150-152 °C
- Solubility: Soluble in organic solvents like ethanol and methanol but poorly soluble in water.
Reactions
Desipramine undergoes various chemical reactions typical for amines and aromatic compounds. Notable reactions include:
- N-Alkylation: Can react with alkyl halides to form quaternary ammonium salts.
- Hydroxylation: Desipramine can be metabolized in vivo to form 2-hydroxydesipramine, which is an active metabolite contributing to its pharmacological effects .
Technical Details
The stability of desipramine under different pH conditions has been studied, revealing that it remains stable in acidic environments but may degrade under prolonged exposure to alkaline conditions.
Desipramine primarily acts by inhibiting the reuptake of norepinephrine at presynaptic neuronal membranes. This action increases the levels of norepinephrine available for neurotransmission, which is crucial for mood regulation. Additionally, desipramine has some affinity for serotonin receptors, although its primary mechanism remains norepinephrine reuptake inhibition.
Process and Data
Research indicates that desipramine’s effects on norepinephrine levels contribute to its efficacy in treating depressive disorders. Studies utilizing positron emission tomography have shown increased norepinephrine transporter occupancy correlating with clinical improvement .
Physical Properties
- Appearance: White to off-white crystalline powder.
- Odor: Odorless.
- Density: Approximately 1.04 g/cm³.
Chemical Properties
- pKa: Approximately 9.5 (indicating it behaves as a weak base).
- Stability: Stable under normal conditions but sensitive to light and moisture.
Relevant analyses have shown that desipramine’s solubility profile affects its bioavailability and therapeutic efficacy, necessitating careful formulation in pharmaceutical applications .
Desipramine is primarily used in clinical settings for:
- Treatment of Depression: Effective for major depressive disorder.
- Anxiety Disorders: Sometimes prescribed off-label for anxiety management.
- Pain Management: Utilized in neuropathic pain syndromes due to its analgesic properties.
Moreover, desipramine has been studied for its potential roles in treating other conditions such as attention-deficit hyperactivity disorder and post-traumatic stress disorder due to its influence on neurotransmitter systems .
Neurotransmitter Reuptake Inhibition Dynamics
Noradrenergic vs. Serotonergic Selectivity Gradients
Desipramine is characterized by its potent and relatively selective inhibition of the norepinephrine transporter (NET). Binding studies reveal a Ki value of 0.63–3.5 nM for human NET, compared to 17.6–163 nM for the serotonin transporter (SERT), indicating a 25- to 400-fold higher affinity for NET [1] [3] [7]. This selectivity arises from desipramine’s structural interaction with the extracellular cavity of NET, where it stabilizes the transporter’s closed conformation via a salt bridge with residue D401 and hydrophobic interactions with F320, preventing norepinephrine reuptake [5].
However, the active metabolite desmethyldesipramine exhibits altered selectivity. In rat models, it shows a 12-fold higher affinity for SERT (Ki = 12.8 nM) than NET (Ki = 153 nM), suggesting that chronic desipramine administration may indirectly enhance serotonergic neurotransmission [2] [4]. This shift underscores the dynamic interplay between parent compounds and metabolites in vivo.
Comparative Affinity Analysis Across Tricyclic Analogues
Among tricyclic antidepressants (TCAs), desipramine demonstrates the highest NET selectivity. Key affinity comparisons include:
Table 1: Reuptake Inhibition Profiles of Selected Tricyclic Antidepressants
| Compound | NET Ki (nM) | SERT Ki (nM) | NET:SERT Selectivity Ratio |
|---|---|---|---|
| Desipramine | 0.63–3.5 | 17.6–163 | 25- to 400-fold |
| Nortriptyline | 4.4–18 | 18–200 | 4- to 10-fold |
| Amitriptyline | 20–100 | 2.8–35 | 0.3- to 5-fold |
| Clomipramine | 38–85 | 0.14–0.6 | 0.01- to 0.05-fold |
Desipramine
- CAS No.
- 50-47-5
- Chemical Name:
- Desipramine
- Synonyms
- DMI 50475;Pentofran;Sertofran;Desipramin;Pertrofane;esipramine;Desipramine;Desimpramine;Desimipramine;Norimipramine
- CBNumber:
- CB3257775
- Molecular Formula:
- C18H22N2
- Molecular Weight:
- 266.38
- MDL Number:
- MFCD00242884
- MOL File:
- 50-47-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | AA00DEIS | 100mg | $238 |
| (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | AA00DEIS | 250mg | $298 |
| (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | AA00DEIS | 500mg | $383 |
| (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | AA00DEIS | 1g | $529 |
| 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine 95.00% | Y225274 | 100MG | $210 |
| Melting point | 212°C |
|---|---|
| Boiling point | bp0.02 172-174° |
| Density | 0.9934 (rough estimate) |
| refractive index | 1.5200 (estimate) |
| pka | pKa 10.21(-)(H2O t=20) (Uncertain) |
| form | powder |
| color | white |
| FDA UNII | TG537D343B |
| ATC code | N06AA01 |
| EPA Substance Registry System | Desipramine (50-47-5) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) | ![]() ![]() GHS08,GHS07 |
|---|---|
| Signal word | Danger |
| Hazard statements | H370-H336-H302 |
| Precautionary statements | P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P403+P233-P405-P501-P260-P264-P270-P307+P311-P321-P405-P501 |
| Hazard Codes | Xn |
| Risk Statements | 20/21/22 |
| Safety Statements | 36 |
| WGK Germany | 3 |
| Hazardous Substances Data | 50-47-5(Hazardous Substances Data) |
| REACH Registrations | Active |
Desipramine price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| aablocks | AA00DEIS | (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | 50-47-5 | 100mg | $238 | 2026-05-28 | Buy |
| aablocks | AA00DEIS | (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | 50-47-5 | 250mg | $298 | 2026-05-28 | Buy |
| aablocks | AA00DEIS | (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | 50-47-5 | 500mg | $383 | 2026-05-28 | Buy |
| aablocks | AA00DEIS | (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine >95% | 50-47-5 | 1g | $529 | 2026-05-28 | Buy |
| ACHEMBLOCK | Y225274 | 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine 95.00% | 50-47-5 | 100MG | $210 | 2026-05-27 | Buy |
Desipramine Chemical Properties, Uses, Production
Originator
Pertofran,Geigy,UK,1963
Uses
Desipramine is used for depression of various etiology and in particular for endogenous depression.
Uses
Antidepressant.
Definition
ChEBI: A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Manufacturing Process
Oxidative coupling of o-nitrotoluene gives 4,4′-dinitrodibenzyl which is reduced with hydrogen to the diamine. The diamine is pyrolyzed to give dihydrobenzazepine. This is reacted with N-(3-chloropropyl)-Nmethylbenzamine to give N-benzyldesipramine. This is debenzylated by reductive cleavage and then reacted with HCl.
brand name
Norpramin (Sanofi Aventis); Pertofrane (Sanofi Aventis).
Therapeutic Function
Psychostimulant
Mechanism of action
Its antidepressant effect results from increases in the level of NE in CNS synapses, and long-term administration causes a downregulation of α1-adrenoceptors and desensitization of presynaptic α2-receptors, equilibrating the noradrenergic system and, thus, correcting the dysregulated output of depressed patients. The SSRIs do not produce this effect. Desipramine also downregulates the NET, but not the 5-SERT . Substantial loss of NE transporter–binding sites takes 15 days to occur and is accompanied by a marked reduction of NET function in vivo. Desipramine has weak effects on 5-HT reuptake.
Synthesis
Desipramine, 10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenz[b,f] azepine (7.1.13), differs from imipramine in that it contains only one methyl group on the nitrogen atom of the propylamine side chain. The suggested methods of desipramine synthesis are very simple, and the difference lies only in the manner in which the secondary methylamine group is introduced into the structure of the drug.
The first way of synthesis is by the alkylation of 10,11-dihydro-5H-dibenz[b,f]azepine using 1-bromo-3-chloropropane in the presence of sodium amide into a chloro derivative (7.1.12) and the subsequent reaction of this with methylamine, giving desipramine (7.1.13) [18–20].

Finally, a second way of synthesis is from imipramine (7.1.1), which undergoes demethylation by successive reaction with ethyl chloroformate, giving 5-[3-(N-carbethoxy-N-methyl)aminopropyl]-10,11-dihydro-5H-dibenz[b,f]azepine (7.1.15), the alkaline hydrolysis of which leads to desipramine (7.1.13) [23,24].

Metabolism
Desipramine is a dihydrodibenzazepine secondary amine TCA that also is the active metabolite of imipramine. Desipramine appears to have a bioavailability comparable to the other secondary TCAs. Desipramine is distributed into milk in concentrations similar to those present at steady state in maternal plasma. This drug is metabolized primarily by CYP2D6 to its 2-hydroxy metabolite and by CYP1A2 and CYP2C19 to its N-demethylated (primary amine) metabolite . Desipramine exhibits a greater potency and selectivity for the NET than the other secondary TCAs do.
Desipramine Preparation Products And Raw materials
Desipramine’s superior NET affinity stems from its secondary amine structure, which reduces steric hindrance at the transporter’s active site compared to tertiary amines (e.g., imipramine). Molecular analyses confirm that its three-ring system and methylaminopropyl side chain optimize binding to NET’s hydrophobic pocket [5] [7].
Receptor Modulation Pathways
Physical Description
XLogP3
Hydrogen Bond Acceptor Count
Hydrogen Bond Donor Count
Exact Mass
Monoisotopic Mass
Boiling Point
Heavy Atom Count
LogP
4.9 (LogP)
log Kow = 4.90
3.7
Decomposition
- Product Name: Desipramine
- Molecular Weight: 266.38068
- Molecular Formula: C18H22N2
- Synonyms: [14C]-Desipramine; [3H]-Desipramine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenz(b,f)azepin; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine;
-
Desipramine | 50-47-5 – ChemicalBook
3 days ago · Desipramine (CAS 50-47-5) information, including chemical properties, structure, melting point, boiling point, density, …
-
Boiling point: bp0.02 172-174°
-
Melting point: 212°C
-
Density: 0.9934 (rough estimate)
-
refractive index: 1.5200 (estimate)
-
2-Hydroxy Desipramine-d3
2-Hydroxy Desipramine-d3 information, including chemical properties, structure, …
-
Imipramine N-Oxide
IMIPRAMINE N-OXIDE (CAS 6829-98-7) information, including chemical …
-
Desipramine-2,4,6,8-D4 HCL
DESIPRAMINE-2,4,6,8-D4 HCL (CAS 61361-34-0) information, including …
-
Desipramine Hydrochloride
Desipramine hydrochloride (CAS 58-28-6) information, including chemical …
-
Trimipramine Maleate Salt
Trimipramine maleate salt (CAS 521-78-8) information, including chemical …
-
-
Desipramine 50-47-5 – Buy High-Purity NET Inhibitor & CYP2D6 Probe
Source high-purity Desipramine (CAS 50-47-5), the definitive selective NET inhibitor (KD 0.83 nM) & CYP2D6 probe substrate for …
-
Desipramine | 50-47-5 – ChemicalBook
3 days ago · Desipramine is used for depression of various etiology and in particular for endogenous depression. ChEBI: A …
-
Boiling point: bp0.02 172-174°
-
Melting point: 212°C
-
Density: 0.9934 (rough estimate)
-
refractive index: 1.5200 (estimate)
-
-
Desipramine (CAS 50-47-5) | NET Inhibitor | BenchChem
Buy Desipramine (CAS 50-47-5) from BenchChem. Selective NET inhibitor (Kd 0.83 nM) with ~21-fold NET/SERT selectivity & …
-
Buy Desipramine (EVT-291916) | 50-47-5 – evitachem.com
Desipramine enhances monoamine neurotransmission in certain areas of the brain by inhibiting the re-uptake of noradrenaline and …
-
CAS No : 50-47-5 | Product Name : Desipramine – API – Pharmaffiliates
Buy highly pure Desipramine – API, CAS No : 50-47-5, Mol.Formula : C18H22N2, Mol.Weight : 266.39, from Pharmaffiliates. Login as …
Desipramine | S580057 | smolecule
Buy Desipramine (CAS No. 50-47-5) from Smolecule. Molecular Formula: C18H22N2. Molecular Weight: 266.4 g/mol. Desipramine …
-
50-47-5 | desipramine
Cas No:50-47-5; Chemical Name:desipramine; Molecular Formula:C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>; Molecular …
-
Desipramine | 50-47-5 – BuyersGuideChem
Please contact all the below listed distributors/manufacturers for Desipramine and ask for prices, package standards and transport …
-
50-47-5 – Desipramine – Sale from Quality Suppliers – Guidechem
Explore the best Desipramine price and the most comprehensive Desipramine supplier on Guidechem. Find the chemical you need …









Reviews
There are no reviews yet.